Nuvelo & Amgen 50/50 Partnership
Alfimeprase identified through research programs at Amgen
Partnered with Amgen in January 2002
50/50 cost/profit sharing
Amgen received warrants, no up front cash
Nuvelo pays for development until we match Amgen’s investment (~ mid Phase 3)
Deal structure leverages respective strengths of each company